Avidity Partners Management’s Vir Biotechnology VIR Stock Holding History

Avidity Partners Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.29M	Sell	519,300 -430,700	-45%	-$4.1M	0.85%	18
2026 Q1	$8.51M	Buy	+950,000	New	+$7.57M	1.72%	12
2023 Q3	–	Sell	-1,425,000	Closed	-$35M	–	102
2023 Q2	$35M	Sell	1,425,000 -215,200	-13%	-$5.4M	1.22%	35
2023 Q1	$38.2M	Buy	1,640,200 +790,200	+93%	+$20.2M	1.27%	30
2022 Q4	$21.5M	Buy	+850,000	New	+$20.8M	0.47%	49
2022 Q3	–	Sell	-758,211	Closed	-$19.3M	–	107
2022 Q2	$19.3M	Sell	758,211 -21,789	-3%	-$509K	0.44%	39
2022 Q1	$20.1M	Buy	780,000 +80,000	+11%	+$2.37M	0.42%	53
2021 Q4	$29.3M	Buy	700,000 +185,000	+36%	+$7.25M	0.62%	48
2021 Q3	$22.4M	Buy	515,000 +353,000	+218%	+$15.3M	0.5%	52
2021 Q2	$7.66M	Buy	+162,000	New	+$7.37M	0.21%	80
2020 Q3	–	Sell	-620,600	Closed	-$25.4M	–	87
2020 Q2	$25.4M	Buy	+620,600	New	+$20.8M	1.63%	21

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Avidity Partners Management's VIR Position: Q2 2026 in Review

Avidity Partners Management reduced its Vir Biotechnology (VIR) stake by 45% in Q2 2026, selling an estimated $4.1M and leaving 519,300 shares worth $5.29M. The position accounts for 0.85% of the portfolio, ranked #18.

Avidity Partners Management first reported a position in VIR in Q2 2020 and has held it in 11 quarters since. The position peaked at $38.2M in Q1 2023. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Avidity Partners Management held 519,300 shares of Vir Biotechnology worth $5.29M as of Q2 2026.
Avidity Partners Management sold 430,700 Vir Biotechnology shares in Q2 2026, an estimated $4.1M.
Vir Biotechnology made up 0.85% of Avidity Partners Management's portfolio in Q2 2026, its #18 holding.
Avidity Partners Management first reported a position in Vir Biotechnology in Q2 2020 and has held it in 11 quarters since.
Avidity Partners Management's Vir Biotechnology position peaked at $38.2M in Q1 2023.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.